Zanubrutinib vs. Ibrutinib Patient Power Video... - CLL Support

CLL Support

24,050 members40,913 posts

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

lankisterguy profile image
lankisterguyAdministratorVolunteer
13 Replies

In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over Ibrutinib - especially for 17p and patients with heart risks.

patientpower.info/chronic-l...?

Watch as Jennifer Brown, MD, PhD, Director, CLL Center, Dana Farber, updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022 American Society of Hematology (ASH) Annual Meeting, including the results of the ALPINE study and the new BTK inhibitors.

-

Len

Written by
lankisterguy profile image
lankisterguy
Administrator
To view profiles and participate in discussions please or .
Read more about...
13 Replies
Chemtrails-USA profile image
Chemtrails-USA

”….will be our new standard of care BTK inhibitor.”

Was the good doctor referring only to high risk, previously treated CLL patients?

- Bobby

lankisterguy profile image
lankisterguyAdministratorVolunteer in reply toChemtrails-USA

Hi Chemtrails-USA,

I believe she is indicating that the early / young data shows the strongest benefit to those high risk patients. It will take more time to see if the future data and other studies show a strong or moderate benefit to untreated or other genetic profiles.

-

The latest NCCN guidelines recommend Zanubrutinib for all CLL patients - see:

ajmc.com/view/nccn-updates-...

Even though the USA FDA has not approved Zanu for any CLL applications yet.

-

The EU & UK may get there first- see: healthunlocked.com/cllsuppo...

healthunlocked.com/cllsuppo...

Len

Rico49 profile image
Rico49 in reply tolankisterguy

Good morning. Any insight into what's the hold up at FDA in US? Secondly, is it reasonable to assume Zanubrutinib would penetrate the blood brain barrier like acali and ibrutinib? Thank you

lankisterguy profile image
lankisterguyAdministratorVolunteer in reply toRico49

Wow those questions are way above my pay grade, you may want to ask your CLL expert doctor for those

Rico49 profile image
Rico49 in reply tolankisterguy

Thanks- I just found where it may be approved in Jan 2023??

Thundercat2 profile image
Thundercat2

I needed this today thanks for sharing Len! I think you meant 2022 in your post however not 2002:)

lankisterguy profile image
lankisterguyAdministratorVolunteer in reply toThundercat2

Thanks for catching that one- Patient Power gets credit for that typo- LOL

Denisguay profile image
Denisguay

2002--?

lankisterguy profile image
lankisterguyAdministratorVolunteer in reply toDenisguay

Thanks for catching that one- Patient Power gets credit for that typo- LOL

Catnap7 profile image
Catnap7

Thank you very much! 🐈🐈

bennevisplace profile image
bennevisplace

Len, does one have to register for this content? None of the videos work for me.

lankisterguy profile image
lankisterguyAdministratorVolunteer in reply tobennevisplace

Yes, you need to register- giving your email address to see the videos

bennevisplace profile image
bennevisplace in reply tolankisterguy

Thanks!

Not what you're looking for?

You may also like...

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

Hi, Just back from a frenetic and fantastic ASH, but still have news to share from ASCO. But first...
bkoffman profile image
CLL CURE Hero

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in

Ibrutinib Slow but steady foreward movement.

Slowly things move forwards… New Marketing Authorisation Application Submitted to EMA for...
Kwenda profile image

New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors

MS-553 is a protein kinase C-beta (PKCß) inhibitor designed to be an alternative treatment option...
spi3 profile image

Breaking news form ASH conference: looks like Ibrutinib May be better than FCR for some patients

#ASH18 #LBA | A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard...
Newchallnge profile image

Moderation team

See all
Newdawn profile image
NewdawnAdministrator
lankisterguy profile image
lankisterguyAdministrator
CLLerinOz profile image
CLLerinOzAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.